Compare LAKE & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LAKE | LUCD |
|---|---|---|
| Founded | 1982 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 145.3M | 132.4M |
| IPO Year | 1986 | 2021 |
| Metric | LAKE | LUCD |
|---|---|---|
| Price | $15.09 | $1.01 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $25.00 | $3.88 |
| AVG Volume (30 Days) | 94.2K | ★ 646.2K |
| Earning Date | 12-09-2025 | 11-12-2025 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $191,631,000.00 | $4,399,000.00 |
| Revenue This Year | $29.73 | $13.30 |
| Revenue Next Year | $8.45 | $155.58 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 39.13 | 5.01 |
| 52 Week Low | $12.76 | $0.75 |
| 52 Week High | $27.28 | $1.80 |
| Indicator | LAKE | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 38.39 |
| Support Level | $13.51 | $1.00 |
| Resistance Level | $15.24 | $1.10 |
| Average True Range (ATR) | 0.62 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 46.47 | 7.20 |
Lakeland Industries Inc manufactures and sells safety garments and accessories for the industrial protective clothing market. Its product segments include Disposables, Chemicals, Fire, Gloves, High Visibility, High-Performance Wear, and Wovens. Its customers include integrated oil, chemical/petrochemical, utilities, automobile, steel, glass, construction, smelting, munition plants, janitorial, pharmaceutical, and mortuaries, as well as scientific and medical laboratories. Its geographical segments include the United States, Latin America, Canada, Asia, Mexico, Europe (United Kingdom), and Other Foreign.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.